Major neurodevelopmental disability at childhood · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability at childhood · Neonates, including term neonates (gestational age ≥ 37 weeks), late preterm neonates (35 to 37 weeks' gestation) and preterm neonates (<…
1 finding from 1 review
Major neurodevelopmental disability at childhood · infants with perinatal asphyxia
It is very uncertain whether barbiturate treatment changes major neurodevelopmental disability compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · infants with perinatal asphyxia
It is very uncertain whether barbiturate treatment changes death or major neurodevelopmental disability compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Major neurodevelopmental disability in infancy · late preterm or term newborns with hypoxic‐ischaemic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability ‒not reported · very preterm infants with or at risk of germinal matrix‐intraventricular haemorrhage in preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Major neurodevelopmental disability at school age · late preterm or term newborns with hypoxic‐ischaemic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants prior to extubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Intervention not reported
Death or major neurodevelopmental disability in infancy · late preterm or term newborns with hypoxic‐ischaemic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants with apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants prior to extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes major neurodevelopmental disability in children aged 3 to 5 years CA compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Major neurodevelopmental disability in children aged 18 to 24 months CA · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found